Buy Tesamorelin 10 mg in Australia
Tesamorelin 10 mg is sold in Australia to laboratories and researchers through Australian Research Peptides — $139.99, in stock, with dispatch on the day for orders paid before 12pm Sydney time on a business day. Tesamorelin's 10 mg certificate records 99.290% purity. Tesamorelin is a synthetic GHRH analogue studied in endocrine and growth-hormone-axis research, and laboratories measure it by how tightly it binds GHRH receptors. The vial holds freeze-dried powder of the full 44-amino-acid growth-hormone-releasing hormone chain, with a hex-3-enoyl group on its N-terminal tyrosine, HPLC-assayed and sealed in tamper-evident glass. In vitro research purposes only.
GHRH and Secretagogue Research · Lyophilised Powder · HPLC-tested · SKU 96235
$139.99
1
Presentation
10 mg per vial
Grade
High-Purity Research Grade
Form
Lyophilised Powder
Category
GHRH and Secretagogue Research
Same-day dispatch on business-day orders completed before 12pm Sydney time, Mon–Fri
Tracked shipping Australia-wide ·typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
Batch certificates — published in the COA library
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. ARP gives no usage, medical or therapeutic guidance of its own.
Tesamorelin · 10 mg
$139.99
Browse all GHRH and Secretagogue Research
About Tesamorelin
Tesamorelin is an analogue of growth-hormone-releasing hormone, usually shortened to GHRH. An analogue copies the structure of another molecule and changes one part of it. GHRH is the endogenous ligand for the GHRH receptor, and tesamorelin is a longer-lasting analogue of that ligand. Laboratory work characterises it at that receptor.
The vial holds the full 44-amino-acid chain of human GHRH. A hex-3-enoyl group sits on the tyrosine at the N-terminal end, and that is the piece the natural hormone does not have. Published records say the N-terminal part was modified to improve the molecule's stability. Length is what separates tesamorelin from ARP's other growth-hormone listing: the CJC-1295 vial carries a 29-amino-acid fragment analogue instead.
Australian Research Peptides holds tesamorelin as a laboratory reference material for in vitro work in glassware and cell culture. It is assayed by HPLC before release, and the certificates ARP has published are collected in its CoA library. The material is not supplied for use in people or animals, and ARP makes no claim about what it does in either.
The listing is a single 10 mg vial of freeze-dried powder, and the compound is written and searched as tesamorelin, tesamorelin peptide, tesamorelin 10 mg and simply tesa — all of them the same GHRH analogue. Stock is held locally, so an order is not waiting on an overseas consignment or an import step.
BAC water (bacteriostatic water) is also in our range.
The peptide calculator works out the mg/mL concentration of a reconstituted vial.
Content reviewed
Further reading: Peptide Types, Categories and Blends · Tesamorelin: What It Is and Why It Is a GHRH Analogue · Where Is the Best Place to Buy Peptides in Australia?
Tesamorelin specifications, storage and shipping
- Compound: Tesamorelin
- Also known as: Tesamorelin
- Class: Synthetic growth-hormone-releasing hormone (GHRH) analogue, full-length sequence
- Appearance: White to off-white lyophilised powder
- Sizes & SKUs: 10 mg (96235)
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: High-purity research grade
- Purity verification: HPLC-assayed to a minimum of 99% purity — the measured result is stated on the published Certificate of Analysis
- Identity confirmation: Mass spectrometry
- Certificates: issued by Janoshik, an independent laboratory, and published in the COA library
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
Tesamorelin is HPLC-tested for purity and confirmed by mass spectrometry for identity. The full laboratory report is published in the COA library. Tesamorelin is tested by Janoshik, an independent laboratory, commissioned by the manufacturer rather than by Australian Research Peptides.
- Tesamorelin 10 mg: assayed purity 99.290% · measured content 10.59 mg · laboratory batch R2026 · analysed 13 May 2026
Business-day orders before 12pm Sydney time are dispatched the same day with tracked shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about Tesamorelin
This question guide from Australian Research Peptides covers Tesamorelin in Australia: what the listing contains, live buying and delivery questions, research context, handling, testing and comparisons. Start with the quick answers, then open the topic group that matches your search.
Buying, price and availability
Tesamorelin is sold in Australia by Australian Research Peptides, which lists it as a single 10 mg vial of freeze-dried powder filed under GHRH and Secretagogue Research. An order completed on a weekday morning, ahead of the 12pm Sydney time cut-off, leaves that same day. Everything ARP sends goes out from within Australia, so delivery is domestic — Express or standard tracked — with no import step to wait on.
Tesamorelin is sold in Australia for in vitro research purposes only, never as a medicine. Australian Research Peptides does not supply it as a therapeutic good, a supplement or a food, and it is not intended for human or animal use. Any figure quoted alongside Tesamorelin describes the vial or the solution made from it, never a direction to a person.
Tesamorelin is supplied by Australian Research Peptides to laboratories, universities and independent researchers working on the growth-hormone axis, for in vitro research in glassware and cell culture only. It is a research compound, not a therapeutic good or a supplement. ARP sells it to no member of the public for personal use and publishes no usage guidance for it.
Tesamorelin is named on the WADA Prohibited List, which Sport Integrity Australia administers in Australia: it sits with the growth-hormone-releasing hormone analogues in section S2.2, beside sermorelin and CJC-1295, and that group is prohibited at all times. ARP does not rule on any compound's status in sport, and supplies Tesamorelin only to laboratories and researchers for in vitro research.
Identity, names and exact format
Australian Research Peptides carries Tesamorelin in one format only, a 10 mg vial, so there is no 5 mg or 20 mg line to weigh against it here. The 10 mg vial suits shorter studies, first-run characterisation, or a researcher assessing the compound before committing to a larger quantity. Where a longer study calls for more material, the answer at ARP is a second 10 mg vial rather than a different size — same compound, same grade, only the quantity ordered changes.
The hex-3-enoyl group is a short fatty chain fixed to the tyrosine at tesamorelin's N-terminal end. The published reason for it, recorded by LiverTox, is stability. Changing that end of the molecule improves how the peptide holds up to handling and storage. That is a fact about the molecule, not a claim about an effect. Strip it away and what is left is the plain GHRH sequence.
Tesamorelin is studied in growth-hormone-axis research as a synthetic agonist of the GHRH receptor, the receptor that growth-hormone-releasing hormone binds. Laboratory work measures how tightly it binds that receptor and the cyclic-AMP signal the receptor passes into the cell once it is switched on. Tesamorelin reaches laboratories and researchers as a bench material only, and ARP claims no medical or cosmetic effect for it.
Reconstitution turns Tesamorelin's freeze-dried powder into a solution, normally using a suitable diluent. Let the sealed Tesamorelin vial reach ambient temperature first. Tesamorelin takes the liquid best down the glass wall, never dropped directly onto the dry cake. Roll or swirl it gently, never shake, and chill what you make.
Dissolved Tesamorelin is stored at 2–8 °C across an eight-to-twelve-week working life, the condition Australian Research Peptides states for reconstituted material. Tesamorelin runs 44 amino acids, the longest chain ARP catalogues, and more residues mean more bonds for water to attack. Its hex-3-enoyl cap is a structural modification made for stability, which is a separate question from how the peptide holds up in glass.
Tesamorelin is not sold at Chemist Warehouse or at any other Australian pharmacy, and it is not available over the counter: it is a laboratory research compound, not a product a pharmacist dispenses. Australian Research Peptides sells Tesamorelin online as a 10 mg vial of freeze-dried powder, supplied to laboratories and researchers for in vitro research only.
Research context and evidence
Tesamorelin binds the GHRH receptor, a G-protein-coupled receptor, and that affinity is what the molecule is characterised by in binding assays. Its 44-residue chain and the hex-3-enoyl group on the N-terminal tyrosine are the structural features that define it against the native hormone. Australian Research Peptides reports receptor pharmacology as published and makes no claim about the research material on this page.
Tesamorelin contains 44 amino acids, the complete chain of human growth-hormone-releasing hormone rather than a shortened piece of it. It is therefore classed as a full-length sequence. The count covers the peptide chain only. The hex-3-enoyl group at one end is a fatty acyl group, not an amino acid, so it sits outside the 44. No residue-by-residue sequence is published on this page.
Tesamorelin is a synthetic, full-length analogue of human growth-hormone-releasing hormone (GHRH) with 44 amino acids and a hex-3-enoyl group at its N-terminal end. It is studied in endocrine research on the growth-hormone axis, the chain of signals controlling when growth hormone is released. Research covers GHRH-receptor binding and pharmacology in cell culture and other in vitro models. Australian Research Peptides supplies this material for in vitro laboratory work and claims no effect for it.
Tesamorelin is not growth hormone and holds none of it: it is a 44-amino-acid copy of growth-hormone-releasing hormone, the upstream signal that arrives at the pituitary gland. Growth hormone itself is a far larger protein that the pituitary makes; tesamorelin is the releasing signal rather than the hormone released. The distinction matters when reading a specification, because a Tesamorelin vial holds the 44-residue analogue and nothing else.
Tesamorelin is supplied as one 10 mg vial of off-white freeze-dried cake at the HPLC Verified grade, sealed under a tamper-evident closure, and Australian Research Peptides carries no other size of it. The 10 mg fill is established by weight at filling, while the assay figure for that lot is read off its own batch document rather than off the listing. No diluent or other consumable is packed with it.
Tesamorelin needs refrigeration from the point you take delivery rather than during transit, because sealed lyophilised peptides tolerate ambient post — which is why the vial travels without a cold chain and arrives stable. Cold storage matters most once the powder has been dissolved. A Tesamorelin vial that arrives warm and still sealed is not a spoiled vial.
That is the correct appearance: Tesamorelin dries to an off-white cake of ten milligrams and, although the molecule is a 44-residue chain and long by peptide standards, that mass still barely coats the bottom. Freeze-drying reduces a frozen solution to its solids alone. Movement in the post can crumble the cake into dust that scatters up the walls, leaving the container reading as untouched.
Tesamorelin is a freeze-dried peptide, and dry is the state it keeps best in. Australian Research Peptides' stated condition for the sealed powder is -20 C, protected from light and moisture. Once dissolved the condition changes to 2-8 C, with a working life of 8 to 12 weeks. Do not refreeze a solution that has thawed. A short warm interval in transit is normal for freeze-dried material.
Handling, storage and measurements
Tesamorelin is supplied as a 10 mg vial and the diluent volume is a bench decision rather than a fixed one, because it changes how concentrated the solution is and not how much peptide is in it. Australian Research Peptides publishes no fill volume for the listing.
Agitation is the usual cause, which is why a reconstituted Tesamorelin vial is rolled gently rather than shaken. Rolling avoids driving air through the liquid, where it shows as a milky suspension that disperses on standing. Cloudiness which persists, or particles remaining once the cake has apparently gone, means the preparation is not sound.
A Tesamorelin vial holds dry peptide only, and a diluent is what dissolves the tesamorelin. Diluent is the term for the liquid that returns a lyophilised powder to solution, and for Tesamorelin it is normally an aqueous one. The vial is measured in milligrams of peptide; the diluent volume is the laboratory's choice.
Tesamorelin comes from Australian Research Peptides, an Australian company working from Sydney rather than routing orders through an overseas warehouse. The listing is the full 44-amino-acid GHRH sequence with its hex-3-enoyl group, one 10 mg vial, HPLC Verified grade. Express Post covers all states and territories, with a 12pm Sydney time weekday cut-off.
Tesamorelin's price in Australia covers a single 10 mg vial and renders live from Australian Research Peptides' catalogue rather than being typed into this answer, so the figure on the listing is always the current one. ARP quotes nothing per milligram, and one price covers the vial whichever batch is on the shelf. Tesamorelin is also offered inside a bundle with retatrutide, which carries its own price on its own page.
A Tesamorelin order qualifies for free shipping once the basket reaches Australian Research Peptides' free-post threshold, which the cart works out for itself at checkout. This answer names no figure deliberately: a threshold typed into copy goes stale on the next reprice and nobody notices. Standard tracked post and Express Post sit at different thresholds, so the answer depends on which service is chosen. The test runs on the pre-discount subtotal, so a discount can never cost an order its free post.
Tesamorelin is bought online from Australian Research Peptides, an Australian research-peptide supplier whose Tesamorelin listing is one 10 mg vial of lyophilised powder. ARP sells direct — it is the supplier rather than a reseller listing another company's stock — so the order is placed with the business that dispatches it. The parcel is released once payment is confirmed, and it posts domestically, so nothing sits between the order and the bench except the post.
Tesamorelin moves in 1–2 business days under Express Post to most destinations and 2–5 under standard tracked post, measured from lodgement rather than from checkout. A tracking number is emailed the moment the parcel goes to the carrier, not when the order is placed, so the gap between those two events is dispatch rather than delay. If tracking has not updated for two business days, contact support.
Tesamorelin is paid for by PayID or by a bank transfer sent from the buyer's own account; wallets and cryptocurrency are not accepted. A PayID or bank transfer carries a unique order reference that must go in the payment description, and that reference is what links a payment back to its Tesamorelin order — reconciliation is manual, so a transfer arriving without one has to be matched by hand against name and amount, which delays dispatch and occasionally cannot be resolved at all.
Tesamorelin is sold on its own: the 10 mg vial from Australian Research Peptides holds tesamorelin alone, with no second peptide blended into it. When an order includes other compounds, each vial is sealed separately and all of them travel in one parcel, so nothing is combined before it reaches the laboratory.
Testing and batch documents
Tesamorelin and GLP-1 peptides are studied at different receptors, and the questions the two literatures ask are different as well. Tesamorelin acts at the GHRH receptor and is studied in growth-hormone-axis research. GLP-1 peptides act at the GLP-1 receptor and are studied in incretin-signalling research. Australian Research Peptides supplies tesamorelin to laboratories and researchers for in vitro research only.
Ordering, payment and Australian delivery
ChEBI records tesamorelin as the free base, the peptide on its own, at an average mass of 5135.863 with the formula C221H366N72O67S. A salt such as the acetate weighs more, and Australian Research Peptides has not confirmed which form its Tesamorelin vial holds, so the figure is the database value for the free base rather than a specification of what is sealed in the glass.
Tesamorelin bought from Australian Research Peptides involves no importing at all: ARP supplies it from Sydney, so an order crosses no border and waits on no clearance, which is why domestic stock reaches a bench faster than an overseas consignment. Anyone importing tesamorelin themselves meets the conditions the TGA publishes for bringing in goods it has not assessed. Those conditions govern importing; they say nothing about what the material is once it is here, and nothing about the obligations of whoever holds it.
Tesamorelin batches supplied by Australian Research Peptides are analysed by HPLC at an independent laboratory, commissioned by the manufacturer, before release, and where a certificate has been published for a listing it is filed in ARP's CoA library and linked from that listing. A certificate records identity and measured purity for one named lot, and its figure belongs to that lot rather than to the listing as a whole. A matching certificate is currently published for this product and strength. Open the 10 mg certificate.
Tesamorelin is analysed by HPLC before Australian Research Peptides releases it, HPLC being the separation method behind the HPLC Verified grade shown on the listing. Identity carries as much weight as purity here, because shorter fragment analogues of the same hormone sit in the same category and a 44-residue chain has to be told apart from a 29-residue one. The certificate ARP publishes is the laboratory's own report for the lot analysed.
Access and regulatory questions
Tesamorelin is also known as TH9507, its development code, and the same code is sometimes written TH-9507 with a hyphen. Chemical registries list it as N-[(3E)-hex-3-enoyl]tyrosyl hGRF(1-44) amide, and the literature often calls it simply a full-length GHRH analogue. Australian Research Peptides maps the shorthand tesa to the listing, and the name is frequently mistyped as tesamorilin. Whichever term you searched, the vial ships from inside Australia, so nothing waits on customs.
Tesamorelin acetate is the acetate salt of the same 44-residue GHRH analogue — identical peptide, different counter-ion — and Australian Research Peptides has not confirmed which form its vial holds, so the listing does not call it the acetate. The two forms carry separate registry numbers: CAS 218949-48-5 for the free base and 804475-66-9 for the acetate. That unconfirmed form is also why molecular formula and mass stay out of the specification table, since both values differ between them.
Tesamorelin and CJC-1295 both act at the GHRH receptor and differ in chain length, while ipamorelin acts at a different receptor altogether. Tesamorelin is the whole 44-amino-acid GHRH chain with a hex-3-enoyl group at one end; CJC-1295 (no DAC), also called Modified GRF (1-29), is a 29-residue fragment analogue; ipamorelin is five residues and binds the growth hormone secretagogue receptor, the one ghrelin occupies. Australian Research Peptides lists CJC-1295 and ipamorelin together as one pre-blended vial, so that vial holds two molecules where a Tesamorelin vial holds one. No published study has compared the three head to head.
Tesamorelin and sermorelin are different molecules, and chain length is the difference: sermorelin is the pharmaceutical form of GHRH (1-29), the first 29 residues, while tesamorelin carries all 44 and a hex-3-enoyl group on its N-terminal tyrosine. Australian Research Peptides does not list sermorelin; the vial on this page is tesamorelin only. The two are searched together because both are GHRH analogues sharing the -morelin ending, but they are separate molecules with separate registry entries.
Tesamorelin and retatrutide sit in different receptor families. Tesamorelin is the full 44-amino-acid GHRH sequence and is studied at the GHRH receptor; retatrutide is a man-made peptide studied at three receptors at once, the GIP, GLP-1 and glucagon receptors. The two have never been compared head to head. Australian Research Peptides also sells the two in one bundle, each in its own sealed vial.